Antengene Corporation Presents Latest Data on ATG-022 at J.P. Morgan Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15h ago
0mins
Source: PRnewswire
- Core Clinical Asset Presentation: Antengene showcased the latest data on ATG-022, its core clinical asset targeting CLDN18.2, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, highlighting its potential in treating solid tumors and enhancing the company's market position in biopharmaceuticals.
- Dual-Function Molecule Development: The ATG-125 bispecific ADC targeting B7-H3 and PD-L1 integrates direct cytotoxicity with durable immune activation, with preclinical studies demonstrating superior in vivo efficacy compared to single-target therapies, and an IND submission is planned for Q1 2027, bolstering the company's R&D pipeline.
- Innovative T Cell Activation Platform: Antengene's AnTenGager™ platform features steric hindrance masking technology and “2+1” bivalent binding capabilities aimed at minimizing cytokine release syndrome (CRS) while enhancing efficacy, supporting broad applications in autoimmune diseases and tumor treatments, showcasing significant market potential.
- First-in-Class Drug Development: ATG-207, a globally first-in-class dual-function biologic for T cell-mediated autoimmune diseases, is set to present preclinical data for the first time at an international scientific conference in 2026, underscoring Antengene's ongoing commitment to innovative drug development.
Analyst Views on 06996
Wall Street analysts forecast 06996 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 06996 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 4.230
Low
Averages
High
Current: 4.230
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
